|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile Achillion Pharmaceuticals
Datamonitor, Nov 2007, Pages: 44
Introduction
Achillion is developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. The company has advanced its lead drug candidate, Elvucitabine for the treatment of HIV infection, into Phase 2 clinical trials. In addition, it has also advanced two late-stage preclinical candidates.
Scope
- Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The companys drug discovery pipeline embodies an innovative program-based approach to identifying new infectious disease targets and designing small molecule drugs to attack these targets. Achillion derives revenues from other pharmaceutical and biotechnology companies through licensing and collaboration agreements. Through these agreements, Achillion takes responsibility for preclinical development, regulatory filing and clinical development through the completion of the proof-of-concept clinical trial of potential drug candidates. The companys total revenues decreased from $8.5 million in 2005 to $3.3 million in 2006. This represents a decrease of 61.4% over 2005. The companys only contributor to revenue growth during 2004-2006 was licensing and collaboration payments from Gilead Sciences.
Reasons to Purchase
- Access all the important information and analysis on the company in a single report
- Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
Achillion Pharmaceuticals Inc-Therapeutic Competitors
Premium Company Profile: Discovery Laboratories
Q2 2007 Earnings Call - Achillion Pharmaceuticals, Inc. - Earnings Transcript
Achillion Pharmaceuticals, Inc. - SWOT Analysis
Q2 2007 Earnings Call - Achillion Pharmaceuticals, Inc. - Call Street Report
Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
Achillion Pharmaceuticals, Inc.-Detailed Product Pipeline
Achillion Pharmaceuticals, Inc.-Financial Company Report
Achillion Pharmaceuticals Inc - SWOT Framework Analysis
Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile
|
|
|
|
